AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04018612
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is an analgesic and antipyretic
Trial: NCT00639496
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02462772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
Trial: NCT00558467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01087216
Drug: Bras B : The group control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
Trial: NCT00002596
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02176655
Drug: VVD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Trial: NCT02176655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
Trial: NCT01155180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02969200
Drug: Enzyme replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
Trial: NCT03693183
Drug: Ketorolac/HPMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
Trial: NCT00002875
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00556946
Drug: Combined Photodynamic & Pulsed Dye Laser Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
Trial: NCT00396656
Drug: Hydrochlorothiazide (HCTZ))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 or 25 mg tablets orally once a day (od) in the morning.
Trial: NCT00765336
Drug: minocycline extended release
RxNorm normalized name: minocycline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg extended release minocycline HCL, once daily for 84 days.
Trial: NCT00656825
Drug: P144 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P144 cream will be given at a dose of 100 μg/mL
Trial: NCT00656825
Drug: P144 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P144 cream will be given at a dose of 200 μg/mL
Trial: NCT00656825
Drug: P144 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P144 cream will be given at a dose of 300 μg/mL
Trial: NCT00656825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be randomly given to 4 subjects in each panel
Trial: NCT01358929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to RO6807952
Trial: NCT01358929
Drug: RO6807952
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating subcutaneous dose
Trial: NCT02972905
Drug: GSK2269557 ELLIPTA DPI
RxNorm normalized name: ECLIPTA PROSTRATA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
Trial: NCT02972905
Drug: Placebo ELLIPTA DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ELLIPTA DPI contains lactose
Trial: NCT01235546
Drug: Azithromycin and standard of care
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
Trial: NCT03299660
Drug: Capecitabine Pill
RxNorm normalized name: capecitabine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
Trial: NCT04031846
Drug: Rotarix™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
Trial: NCT04031846
Drug: Infanrix™ hexa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
Trial: NCT04031846
Drug: V114
RxNorm normalized name: Pneumococcal 15-valent Conjugate Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
Trial: NCT04031846
Drug: Prevenar 13™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
Trial: NCT01235546
Drug: Placebo and standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 cc normal saline, plus standard of care (cephazolin or clindamycin)
Trial: NCT00550043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04201574
Drug: ALY688 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALY688 0.1% Ophthalmic Solution
Trial: NCT04201574
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT01095562
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 Dose 1, ABT-126 Dose 2
Trial: NCT01095562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04273529
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg，po，qn，for 14 days.
Trial: NCT03335488
Drug: NaPBA
RxNorm normalized name: Caffeine 200 MG Oral Powder for Suspension [SNAPBACK STIMULANT POWDERS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose
Trial: NCT01016951
Drug: AZD9164 Turbuhaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg.
Trial: NCT01016951
Drug: Placebo Turbuhaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation via Turbuhaler, MAD
Trial: NCT03349060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Trial: NCT02565628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01977755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03557619
Drug: ethinyl estradiol/levonorgestrel
RxNorm normalized name: ETHINYL ESTRADIOL/LEVONORGESTREL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet; oral
Trial: NCT03222622
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically twice daily for 12 consecutive weeks
Trial: NCT02954601
Drug: ORMD-0801 (bid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2 = ORMD-0801 (bid)
Trial: NCT02954601
Drug: ORMD-0801 (tid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 3 = ORMD-0801 (tid)
Trial: NCT01269216
Drug: 5-FU with leucovorin
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
Trial: NCT00760916
Drug: UT-15C 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UT-15C 1 mg
Trial: NCT00760916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02236962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00318474
Drug: MMF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo only, oral administration
Trial: NCT00318474
Drug: ACEi
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer same as pre-treatment regimen.
Trial: NCT00318474
Drug: FOS
RxNorm normalized name: Fostex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer same as pre-treatment regimen
Trial: NCT00002772
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002772
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00204919
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-monthly placebo capsules
Trial: NCT03833297
Drug: Drugs inducing hepatological toxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce hepatological toxicities
Trial: NCT00277238
Drug: CPG10101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Trial: NCT00277238
Drug: CPG10101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Trial: NCT02333344
Drug: Zoledronic acid 5mg
RxNorm normalized name: ZOLEDRONIC ACID 5MG/BTL INJ,100ML
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: two-year Zoledronic acid 5mg infusion treatment
Trial: NCT03040778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT01543178
Drug: double-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day (double-blind)
Trial: NCT02182492
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg tablet once daily for 3 months
Trial: NCT02182492
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate nasal spray 200 μg/d for 3 months
Trial: NCT00885196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00885196
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04630002
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available as oral tablets.
Trial: NCT04644432
Drug: Medication (A specification is listed under each arm)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drugs and dosages are listed in the description of arms.
Trial: NCT01821235
Drug: Neurontin® (gabapentin) batch B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
Trial: NCT01821235
Drug: Gabasandoz® (gabapentin) batch B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
Trial: NCT02988401
Drug: Placebo (Sterile diluent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
Trial: NCT01394354
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
Trial: NCT04354987
Drug: CKD-391 10/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug T: CKD-391 10/10mg(Other Name: Test Drug)
Trial: NCT04354987
Drug: D090, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D090 and D337 co-administration(Other Name: Reference drug)
Trial: NCT00264667
Drug: GW677954
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01767766
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGR-1202 Daily Oral Dose
Trial: NCT02074358
Drug: Beriplex P/N (4-Factor PCC)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02074358
Drug: Placebo (Saline solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03309943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one dose of Placebo on two separate occasions.
Trial: NCT00023855
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02019264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily
Trial: NCT04303806
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: receive rosuvastatin orally once daily.
Trial: NCT02027454
Drug: GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
Trial: NCT02027454
Drug: GSK1265744 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
Trial: NCT00628212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02025725
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray formulation with vehicle only
Trial: NCT00122837
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02416609
Drug: Gem-based doublets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of Gem-based doublets
Trial: NCT00546377
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02593097
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo twice daily
Trial: NCT05215977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU
Trial: NCT00665431
Drug: PN 400 (VIMOVO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg naproxen/20 mg esomeprazole bid
Trial: NCT00665431
Drug: Rescue Antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid Tablets
Trial: NCT01934582
Drug: UT-15C SR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01934582
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label study drug.
Trial: NCT02151305
Drug: Propofol, remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01487395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
Trial: NCT01397877
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os, 60mg/j, until progression or unacceptable toxicity
Trial: NCT01394731
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01063192
Drug: Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
Trial: NCT00204776
Drug: Capecitabine and Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04104503
Drug: [14C]-Lu AF11167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single iv microdose administered as a 15 minutes infusion
Trial: NCT04104503
Drug: Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT00404391
Drug: Hydrocodone/Acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet every 12 hours
Trial: NCT00404391
Drug: Hydrocodone/Acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every 12 hours
Trial: NCT00404391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets every 12 hours
Trial: NCT01031680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg single oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg single oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg single oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg single oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg single oral dose (females)
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg multiple oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg multiple oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID multiple oral dose
Trial: NCT01521832
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID multiple oral dose (females)
Trial: NCT00003853
Drug: 4'-iodo-4'-deoxydoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02123589
Drug: Deep sedation(midazolam and fentanyl )
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
Trial: NCT02123589
Drug: Deep and daily interruption of sedation(midazolam and fentanyl )
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
Trial: NCT00757042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by subcutaneous or intravenous injection.
Trial: NCT01006187
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium stream spray on arm for 4-10 seconds prior to injection
Trial: NCT02915705
Drug: Oral Phosphate Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet; oral solution; oral powder
Trial: NCT01591382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received ketamine-matching placebo were given saline infusions
Trial: NCT01057147
Drug: placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill one drop in each eye four times daily for 12 weeks.
Trial: NCT00430573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
Trial: NCT01506895
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT03286556
Drug: Autoantibody Reductive Therapy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
Trial: NCT03286556
Drug: Treatment as Usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and steroids
Trial: NCT00317785
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03318861
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously